Dyne Therapeutics, Inc. Stock News

- Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model -

- “The Muscle to Move to the Clinic” Event Will Highlight Preclinical Data Supporting Advancement of Dyne's DM1 and DMD Programs Toward Clinical Trials and Anticipated Timelines, and Feature Leadi

WALTHAM, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with

- New In Vivo Data Also Show Sustained Knockdown of Toxic Human Nuclear DMPK RNA and Foci Reduction -

- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - New In Vivo Data from DM1 and DMD Programs to be Presented at Scientific

- FORCE™ platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line -

- Co-founder Romesh Subramanian, Ph.D., stepping down as chief scientific officer and will serve as an advisor after leading successful R&D and pipeline-building efforts -

Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained knockdown of toxic human nuclear

- Robust Reduction in DMPK RNA in Multiple Muscles at Four Weeks in Novel In Vivo Model Developed by Dyne; Additional In Vitro Data Support Advancement of Lead DM1 Candidate -

Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following presentations on May 14, 2021 Company to host webcast including leading DM1 expert, Dr. Charles Thornton, followin

Edgewise Therapeutics has filed to raise $150 million in an IPO.

The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.

- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4'21 and Q4'22 -

Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease

Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease